142 related articles for article (PubMed ID: 24903479)
1. Effects of the small-molecule inhibitor of integrin α4, TBC3486, on pre-B-ALL cells.
Hsieh YT; Gang EJ; Shishido SN; Kim HN; Pham J; Khazal S; Osborne A; Esguerra ZA; Kwok E; Jang J; Bonig H; Biediger RJ; Vanderslice P; Kim YM
Leukemia; 2014 Oct; 28(10):2101-4. PubMed ID: 24903479
[No Abstract] [Full Text] [Related]
2. Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy.
Hsieh YT; Gang EJ; Geng H; Park E; Huantes S; Chudziak D; Dauber K; Schaefer P; Scharman C; Shimada H; Shojaee S; Klemm L; Parameswaran R; Loh M; Kang ES; Koo HH; Hofmann WK; Andrade J; Crooks GM; Willman CL; Müschen M; Papayannopoulou T; Heisterkamp N; Bönig H; Kim YM
Blood; 2013 Mar; 121(10):1814-8. PubMed ID: 23319569
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
[TBL] [Abstract][Full Text] [Related]
4. The central nervous system microenvironment influences the leukemia transcriptome and enhances leukemia chemo-resistance.
Gaynes JS; Jonart LM; Zamora EA; Naumann JA; Gossai NP; Gordon PM
Haematologica; 2017 Apr; 102(4):e136-e139. PubMed ID: 28034988
[No Abstract] [Full Text] [Related]
5. STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway.
Belton A; Xian L; Huso T; Koo M; Luo LZ; Turkson J; Page BD; Gunning PT; Liu G; Huso DL; Resar LM
Leuk Lymphoma; 2016 Nov; 57(11):2681-4. PubMed ID: 26952843
[No Abstract] [Full Text] [Related]
6. Characterizing the Motility of Chemotherapeutics-Treated Acute Lymphoblastic Leukemia Cells by Time-Lapse Imaging.
Liu HC; Gang EJ; Kim HN; Ruan Y; Ogana H; Wan Z; Bönig H; Shung KK; Kim YM
Cells; 2020 Jun; 9(6):. PubMed ID: 32560076
[TBL] [Abstract][Full Text] [Related]
7. Potent in vivo suppression of inflammation by selectively targeting the high affinity conformation of integrin α4β1.
Vanderslice P; Woodside DG; Caivano AR; Decker ER; Munsch CL; Sherwood SJ; Lejeune WS; Miyamoto YJ; McIntyre BW; Tilton RG; Dixon RA
Biochem Biophys Res Commun; 2010 Oct; 400(4):619-24. PubMed ID: 20807504
[TBL] [Abstract][Full Text] [Related]
8. IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase.
Laranjeira AB; de Vasconcellos JF; Sodek L; Spago MC; Fornazim MC; Tone LG; Brandalise SR; Nowill AE; Yunes JA
Leukemia; 2012 May; 26(5):1001-11. PubMed ID: 22005787
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers.
Pillozzi S; Masselli M; De Lorenzo E; Accordi B; Cilia E; Crociani O; Amedei A; Veltroni M; D'Amico M; Basso G; Becchetti A; Campana D; Arcangeli A
Blood; 2011 Jan; 117(3):902-14. PubMed ID: 21048156
[TBL] [Abstract][Full Text] [Related]
10. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro.
Juarez J; Bradstock KF; Gottlieb DJ; Bendall LJ
Leukemia; 2003 Jul; 17(7):1294-300. PubMed ID: 12835717
[TBL] [Abstract][Full Text] [Related]
11. CD49d and CD49e induce cell adhesion-mediated drug resistance through the nuclear factor-κB pathway in Burkitt lymphoma.
Takeda T; Tsubak M; Genno S; Matsuda T; Yamamoto Y; Ueda E; Imano M; Satou T; Nishida S
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33214335
[TBL] [Abstract][Full Text] [Related]
12. Transcription factor dose links development to disease.
Sigvardsson M
Blood; 2012 Nov; 120(18):3630-1. PubMed ID: 23118213
[No Abstract] [Full Text] [Related]
13. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
14. The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.
Li Z; He S; Look AT
Leukemia; 2019 Jan; 33(1):262-266. PubMed ID: 30008477
[No Abstract] [Full Text] [Related]
15. Effects of CD49d-targeted antisense-oligonucleotide on α4 integrin expression and function of acute lymphoblastic leukemia cells: Results of in vitro and in vivo studies.
Duchartre Y; Bachl S; Kim HN; Gang EJ; Lee S; Liu HC; Shung K; Xu R; Kruse A; Tachas G; Bonig H; Kim YM
PLoS One; 2017; 12(11):e0187684. PubMed ID: 29117236
[TBL] [Abstract][Full Text] [Related]
16. Anticancer drugs: Hitting SYK in B-ALL leukaemia.
Harrison C
Nat Rev Drug Discov; 2014 Jul; 13(7):494. PubMed ID: 24948121
[No Abstract] [Full Text] [Related]
17. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
Frismantas V; Dobay MP; Rinaldi A; Tchinda J; Dunn SH; Kunz J; Richter-Pechanska P; Marovca B; Pail O; Jenni S; Diaz-Flores E; Chang BH; Brown TJ; Collins RH; Uhrig S; Balasubramanian GP; Bandapalli OR; Higi S; Eugster S; Voegeli P; Delorenzi M; Cario G; Loh ML; Schrappe M; Stanulla M; Kulozik AE; Muckenthaler MU; Saha V; Irving JA; Meisel R; Radimerski T; Von Stackelberg A; Eckert C; Tyner JW; Horvath P; Bornhauser BC; Bourquin JP
Blood; 2017 Mar; 129(11):e26-e37. PubMed ID: 28122742
[TBL] [Abstract][Full Text] [Related]
19. Hydrocortisone does not influence glucocorticoid sensitivity of acute lymphoblastic leukemia cells.
Warris LT; van den Heuvel-Eibrink MM; Ariës IM; Pieters R; van den Akker EL; den Boer ML
Haematologica; 2015 Apr; 100(4):e137-9. PubMed ID: 25425687
[No Abstract] [Full Text] [Related]
20. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment.
Juarez J; Dela Pena A; Baraz R; Hewson J; Khoo M; Cisterne A; Fricker S; Fujii N; Bradstock KF; Bendall LJ
Leukemia; 2007 Jun; 21(6):1249-57. PubMed ID: 17410186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
